Martin E. Dowty

Publications by Year

Research Areas

Pharmacogenetics and Drug Metabolism, Cytokine Signaling Pathways and Interactions, Drug Transport and Resistance Mechanisms, Rheumatoid Arthritis Research and Therapies, Biosimilars and Bioanalytical Methods

Most-Cited Works

• → Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)(2011)630 cited
• → Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis(2010)457 cited
• The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.(2016)
• → Plasmid DNA entry into postmitotic nuclei of primary rat myotubes.(1995)269 cited
• → The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans(2014)266 cited
• → Expression of naked plasmids by cultured myotubes and entry of plasmids into T tubules and caveolae of mammalian skeletal muscle(1992)205 cited
• → Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition(2016)191 cited
• → Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S )-2,2-Difluorocyclopropyl)((1 R ,5 S )-3-(2-((1-methyl-1 H -pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)(2018)170 cited
• → Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases(2018)163 cited
• → Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans(2017)160 cited